colorectal liver metastasis
Conditions
Interventions
Sonazoid 
agent.
ultrasound 
based 
on 
Gold Standard:Pathological diagnosis of surgically resected lesions and intraoperative ultrasound diagnosis of non-surgically resected lesions
Sponsors
Peking University Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Clinical and MRI examinations clearly diagnosed colorectal liver metastasis; (2) The number of lesions in the liver = 3.0 x 10^9/L; The absolute value of neutrophils >= 1.5 x 10^9/L; Platelet count >= 100 x 10^9/L; Hemoglobin >= 90 g/L; Serum albumin >= 2.5 g/dL; Liver function: total bilirubin = 50 mL/min (Cockcroft and Gault formula); International normalized ratio (INR) <= 1.5, and activated partial thromboplastin time (APTT) or partial prothrombin time (PTT) <= 1.5 x ULN.
Exclusion criteria
Exclusion criteria: (1) Unable to operate with relevant contraindications for surgery; (2) The patient's compliance is poor, and the disease is expected to be unable to obtain a clear diagnosis; (3) The patient is accompanied by any unstable systemic diseases, including but not limited to: severe infection, uncontrolled diabetes, unstable angina, cerebrovascular accident or transient cerebral ischemia, myocardial infarction, congestive heart failure, Severe arrhythmia, liver, kidney or metabolic diseases that require medication; (4) The patient's accompanying diseases (such as mental illness, etc.) or conditions (such as alcohol or drug abuse, etc.) will increase the patient's risk of receiving ultrasound examinations or affect the patient's compliance with research requirements, or may confuse the research results; (5) Patients who are known to be allergic to ultrasound contrast agents (Senovi or Shizhuoan) or its active ingredients and excipients; (6) Women who are pregnant or breastfeeding or who intend to become pregnant or breastfeeding during the study period; (7) There are contraindications mentioned in the instructions for MRI or ultrasound contrast agents.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SEN, SPE, ACC, AUC of ROC, PPV, NPV;The location and size of the lesion;the location and size of the lesion;Pathological diagnosis and specimen size measurement; | — |
Countries
China
Contacts
Public ContactKun Yan
Peking University Cancer Hospital
Outcome results
None listed